L-iduronate-rich glycosaminoglycans inhibit growth of normal fibroblasts independently of serum or added growth factors.
The effects of various glycosaminoglycans (GAGs) on the growth rate of normal fibroblasts and a fibrosarcoma cell line (HT 1080) were examined. Cells were grown in 96-well microplates in the absence or presence of serum mitogens, epidermal (EGF), platelet-derived (PDGF), acidic fibroblast (aFGF), or basic fibroblast growth factor (bFGF). Cell number was measured by using crystal violet to stain cell nuclei (Westergren-Thorsson, G., Onnervik, P.-O., Fransson, L.-A., and Malmström, A. J. Cell. Phys. 147, 523-530, 1991) and also by using a Coulter counter. In the presence of serum mitogens, L-iduronate (IdoA)-rich GAGs, such as dermatan sulfate, heparin, and highly sulfated heparan sulfate, inhibited proliferation of normal cells (25-35%), whereas HT 1080 cells were unaffected or slightly stimulated. Ham's F-12 supplemented with insulin and transferrin but without growth factors was able to support growth of both cell types. Under these conditions, the IdoA-rich GAGs still suppressed growth of normal cells (40-55%), whereas HT 1080 cells again responded poorly. When growth factors were added proliferation of normal fibroblasts was further stimulated, EGF being the most effective. In the presence of either EGF, PDGF, or bFGF, IdoA-rich GAGs had a sustained inhibitory effect on normal fibroblasts (30-50% at concentrations at or above 10 micrograms/ml). However, in the presence of aFGF, both IdoA-rich and IdoA-poor heparan sulfates enhanced growth (nearly twofold after prolonged exposure) suggesting a stabilization of this growth factor. In general, IdoA-rich GAGs appear to inhibit proliferation of normal cells irrespective of the type of growth factor used. Therefore, GAGs are likely to act directly on cell-derived regulatory components, either before or after internalization. As fibrosarcoma cells were much less sensitive to growth inhibition, they may contain altered receptors for GAGs.
Westergren-Thorsson
G
G
Department of Medical and Physiological Chemistry, University of Lund, Sweden.
Persson
S
S
Isaksson
A
A
Onnervik
P O
PO
Malmström
A
A
Fransson
L A
LA
D001798:Blood Proteins / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003871:Dermatan Sulfate / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects; D005354:Fibrosarcoma / Q000473:pathology*; D006025:Glycosaminoglycans / Q000737:chemistry* / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology*; D006497:Heparan Sulfate / Q000494:pharmacology; D006801:Humans; D007067:Iduronic Acid / Q000032:analysis*; D008168:Lung / Q000166:cytology*; D008934:Mitogens / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D001798:Blood Proteins; D003871:Dermatan Sulfate; D004815:Epidermal Growth Factor; D016220:Fibroblast Growth Factor 1; D016222:Fibroblast Growth Factor 2; D006025:Glycosaminoglycans; D006131:Growth Inhibitors; D006133:Growth Substances; D006497:Heparan Sulfate; D007067:Iduronic Acid; D008934:Mitogens; D010982:Platelet-Derived Growth Factor